Communication

Theoretical Insights from Binding of *Neigleria fowleri* Cell Division Proteins with Amoebicidal Quassinoids

Zarrin Basharat ^{*1}, Shumaila Zaib², Azra Yasmin²

¹ Jamil-ur-Rahman center for Genome Research, Dr. Panjwani Centre for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi-75270, Karachi, Pakistan.

² Microbiology & Biotechnology Research Lab, Department of Environmental Sciences, Fatima Jinnah Women University, Rawalpindi 46000, Pakistan.

* Correspondence: zarrin.iiui@gmail.com

Abstract: The ameboflagellate *Neigleria fowleri*, also known as brain eating amoeba is responsible for fatal primary amoebic meningoencephalitis (PAM) infection in humans. Cell division proteins (CDPs) in *N. fowleri* have been uncharacterized until now, despite their importance in the initiation of cell division and proliferation of the pathogen. Here, we report characterization and structural assembly of eight such proteins associated with division and docking them with anti-amoebic quassinoid compounds. Quassinoids have been implicated as inhibitors of cell proliferation of amoeboid species as well as tumor cells. Here, they were screened computationally to find interaction mechanism as well as binding energies with CDPs of *N. fowleri*. The identified inhibitors could play a role in prevention of cell division and hence, stop *N. fowleri* growth and proliferation during infection. This study supports CDPs as a target for anti-amoebic intervention and identifies quassinoid phytochemical compounds as suitable for optimization into a new therapy against *N. fowleri*.

Keywords: *Neigleria fowleri*; Brain eating amoeba; Primary amoebic meningoencephalitis; Quassinoids, Amoebicidal; Phytotherapy; Molecular docking.

1. Introduction

N. fowleri is considered as an amphizoic amoeba because of its property to survive in a free-living state as well as in the host. In free living form it is found in water or soil and in the host found in human central nervous system [1]. Life cycle of *N. fowleri* is comprised of three stages, Trophozoites (feeding stage), Flagellate (motility stage) and Cysts (surviving). *N. fowleri* enters the human body in the trophozoite form which is infectious stage. Food cups are found on the surface of trophozoites through which they ingest bacteria, fungi, and human tissue [2]. *N. fowleri* passes into the host during recreational activities such as water sports, swimming, cultural practices (use of neti pots) religious practices of Muslims (ablution or “wuzu”) and Hindus (bathing in river Ganges) [3]. *N. fowleri* forces itself into the nasal cavity and after passing through olfactory nerve *N. fowleri* reaches CNS via cribriform plate [2]. This pathogen attacks by releasing cytotoxic molecules in the central nervous system which cause necrosis and lead to primary amoebic meningoencephalitis [4].

PAM was reported for first time in Australia in 1965 although there has been a record of its occurrence as early as 1937 in Virginia, America. Cases have been reported from the America, Australia, Europe and Asia. Rise in temperature is the major factor which contributes to increases PAM infection, as high temperature favours multiplication of the amoeba [5,6]. PAM symptoms are fever, nausea, vomiting, severe headache, stiff neck, altered mental status, hallucinations, seizures, and coma [7]. Overall, this disease is extremely rare but deadly; about 235 PAM cases have been reported worldwide till to date. Reports have been of almost always fatal PAM infection, with survival rate of approximately 5% [8]. In Pakistan alone, 40 deaths have been reported in Karachi

from 2010 to 2015 [7]. The incubation period for PAM is about 5 to 7 days, and infected individual died within a week [1]. From 1962 to 2014, only three people out of 133 infected with *N. fowleri* have survived in the USA [6]. Cerebrospinal fluid smear, PCR and CT scan are normally used to diagnose *N. fowleri* [7].

Drugs that have been used in the past for treatment of PAM include Amphotericin B, Fluconazole, Azithromycin, Miltefosine and Rifamin. These drugs either alter membrane permeability, inhibit protein synthesis or RNA polymerase activity, with side effects like diarrhoea, nausea, chills, vomiting, malaise, heartburn, drowsiness, dizziness and headache [4]. Owing to lack of any vaccine and side effects of antibiotics against *N. fowleri* [9], improved drugs are required for prevention and treatment of *N. fowleri* infection. For the discovery and development of drugs against selected targets, plethora of computational approaches such as comparative genomics, molecular docking and virtual screening are used. Previously, we reported HSP70 as potential therapeutic candidate against *N. fowleri* [10]. CDPs of *N. fowleri* could also serve as important therapeutic candidates. In this study, anti-amoebic quassinoids from literature were mined and used for molecular docking with CDPs of *N. fowleri*. Currently, the authors are also involved in screening large library of quassinoids against different amoebic species and their comparison at ortholog and paralog scale.

2. Method and analysis

Interest in computational drug discovery has been increasing in the recent era and chemicals scaffolds are being explored by researchers for their therapeutic and pharmacological effects [11] using various computational algorithms and softwares. For computational assisted screening of quassinoids against CDPs of *N. fowleri*, CDP sequences were downloaded from the Amoeba Genomics Resource Database (<http://amoebadb.org/amoeba/>). Accession numbers have been mentioned in the Table 1. Phosphorylation potential was obtained from the NetPhos 3.1 server [12]. Interplay of phosphorylation and O- β -glycosylation i.e. Yin-Yang sites were identified using YinOYang server 2.1 [13]. Molecular weight, theoretical pI and grand average of hydrophobicity (GRAVY) were identified using ExPASy tools [14]. TMHMM server [15] was used for assessing the presence of transmembrane helices in the proteins.

Table 1. Different physico-chemical parameters of *N. fowleri* CDPs. Residues in brackets against the third and sixth CDP are the ones showing phosphorylation at residues interacting with quassinoid molecules.

Serial No.	Accession no.	No. of amino acids	Molecular weight	Theoretical pI	GRAVY	Predicted TMHs	No. of phosphorylated residues	No. of YinOYang sites
1	NF0026440	545	60032.69	5.23	-0.579	0	106	25
2	NF0036940	382	45053.14	8.64	-0.188	3	39	3
3	NF0045650	161	19343.08	5.60	-0.635	0	21 (T29, T30)	3
4	NF0080760_2	258	29006.76	6.54	-0.301	0	31	6
5	NF0084440_2	137	15949.08	8.90	0.803	2	8	-
6	NF0090830	398	43473.21	9.89	-0.892	0	79 (T341, S346)	18
7	NF0111200	384	42852.93	7.10	-0.439	0	40	2
8	NF0120690_1	106	12601.94	8.58	0.460	2	8	-

3D structures were predicted using the I-TASSER software suit [16, 17] using templates from the RCSB Protein Data Bank. Quassinoid compounds (Table 2) were downloaded from the PubChem database, optimized and stored in a .mdb database. For docking, protein structures were protonated as well as energy minimized until a gradient of 0.05 was attained. Docking was carried out in

Molecular Operating Environment (MOE) software suite. Parameters for placement: Triangle match and rescoring by London dG and Affinity dG force respectively. Refinement was done through forcefield method. The best structure with least S value was retained for further downstream analysis. Ligand interactions were visualized in 2D [18].

Table 2. Anti-amoebic quassinoids (Reviewed by [19]), used in this study for docking and analysis against CDPs of *N. fowleri*.

Serial no.	Compound	Plant source of isolation	IC50 (μg/ml)	2D structure	Reference
1	Bruceantin	<i>Brucea javanica</i>	0.019		Wright et al., 1988
2	Bruceine A	<i>Brucea javanica</i>	0.097		Wright et al., 1988
3	Bruceine B	<i>Brucea javanica</i>	0.306		Wright et al., 1988
4	Bruceine C	<i>Brucea javanica</i>	0.297		Wright et al., 1988
5	Bruceine D	<i>Brucea javanica</i>	0.386		Wright et al., 1988
6	Brusatol	<i>Brucea javanica</i>	0.062		Wright et al., 1993
7	Ailanthinone	<i>Simarouba amara</i>	0.063		Wright et al., 1988
8	Glaucarubin	<i>Simarouba glauca</i>	1.57		Gillin et al., 1982
9	Glaucarubinone	<i>Simarouba amara</i>	0.168		Wright et al., 1988

10	Glaucarubolone	<i>Brucea antidysentrica</i>	0.12		Kambu, 1990
11	Quassin	<i>Quassia amara</i>	0.5		Keene et al., 1986

3. Results

We are constantly in search of new and better drugs for cure against diseases of almost all types. High-throughput screening, structure based interaction and quantitative structure activity relationship is usually used for guiding bioassays. Isolated molecules may then be developed into drugs with improved clinical action or fewer side effects [19]. There is a lot of scope in investigating the nature derived plant compounds and herbal therapies for their safety and efficacy and harnessing their potential against diseases. Several drugs have been tested for *N. fowleri* caused PAM with varying results [20-30].

Quassinoids are phytoconstituents of several Simaroubaceae species and consist of degraded triterpenes. They have demonstrated activity against viral proteins [31, 32] and cancerous cells [33, 34]. They have also shown pharmacological action against inflammation, insects and ulcer [31]. They bind proteins in amoeba and prevent their proliferation. Their impact on protozoan/amoeba has been reviewed in detail elsewhere [19]. In the quest for new, effective, and safe amoebicidal agents against *N. fowleri*, anti-amoebic quassinoid molecule interactions were identified against CDPs of this pathogen. Each CDP was tested against all eight anti-amoebic quassinoids (mentioned in Table 2) and small molecule with the best ability to bind to the specific CDP was analysed for interacting residues.

All CDPs had different sequence and hence, structures. This demonstrates a pattern of paralog existence and extreme variation of CDP sequences in *N. fowleri*. Molecular interaction did not show conservation of a specific binding residue. Despite this variation of sequence and no conservation of binding site, majority i.e. 3 paralogs showed best affinity for Brucein B molecule. Two CDPs showed maximum affinity for Brusatol (Table 3). Phosphorylation pattern also varied for all paralogs. In two CDPs (Accession no: NF0045650 and NF0090830), two phosphorylated residues made interaction with ligand. One had both threonines while other paralog had one serine and one threonine showing interaction with quassinoids Glaucarubin and Bruceine B respectively. No such pattern was observed for other paralogs. YinOYang sites were present in six CDPs (Table 3) but none showed interplay of phosphorylation and glycosylation at docked site residues.

Since, formulation of plant derived small molecules into drugs, entails screening enormous number of plant extracts followed by the compound isolation and identification of action mechanism, this study could prove useful for guiding such assays. Toxicity tests could then be done to establish safety for the host and specificity of action on pathogen. In the present study, docking was attempted to screen potent amoebicidal quassinoid phytochemicals against CDPs of *N. fowleri*. The study is a preliminary information report and experimental assays are further needed to validate the findings.

Table 3. Protein structure and interaction information for the studied CDPs of *N. fowleri*. Serial numbers refer to the accession numbers mentioned against similar serial numbers in Table 1. depicts polar residue, acidic, basic, hydrophobic, side chain acceptor, side chain donor, backbone acceptor, backbone donor, ligand exposure, receptor exposure, arene-arene, arene cation and black dotted line as proximity contour.

Serial no.	Template PDB	3D structure	Best docked compound	Binding energy value	2D interaction of best docked complex
1	2tma		Brusatol	-3.9002
2	4ry2		Glaucarubione	-6.1092
3	3kkc		Glaucarubin	-3.7145
4	3b5x		Bruceine B	-6.2030

2. De Jonckheere, J. F. Origin and evolution of the worldwide distributed pathogenic amoeboflagellate *Naegleria fowleri*. *Infect Genet Evol* **2011**, 11, 1520-1528.
3. Siddiqui, R.; Khan, N. A. Primary amoebic meningoencephalitis caused by *Naegleria fowleri*: an old enemy presenting new challenges. *PLoS Negl Trop Dis* **2014**, 8, e3017.
4. Pugh, J. J.; Levy, R. A. *Naegleria fowleri*: Diagnosis, Pathophysiology of Brain Inflammation, and Antimicrobial Treatments. *ACS Chem Neurosci* **2016**, 7, 1178-1179.
5. Martinez, A. J.; Visvesvara, G. S. Free-living, amphizoic and opportunistic amebas. *Brain Pathol* **1997**, 7(1), 583-598.
6. Mukhtar, F.; Wazir, M. S. *Naegleria fowleri*: The brain eating amoeba or an enigma?. *J Ayub Med Coll Abbottabad* **2015**, 27, 735-736.
7. Abbas, S. S.; Naveed, S.; Qamar, F.; Ali, Z. B. Enlightenment on *Naegleria fowleri*; a brain eating amoeba-an alarming call. *Int Edu Res J* **2015** 1, 1-3.
8. Panda, A.; Khalil, S.; Mirdha, B. R.; Singh, Y.; Kaushik, S. Prevalence of *Naegleria fowleri* in environmental samples from northern part of India. *PloS one* **2015**, 10, e0137736.
9. Khan, M. M.; Ahmad, I. *Naegleria*: Preventable by water chlorination. *Gomal J Med Sci* **2015**, 13(2).
10. Basharat, Z.; Zaib, S.; Yasmin, A. Computational study of some amoebicidal phytochemicals against heat shock protein of *Naegleria fowleri*. *Gene Rep* **2017a**, 6, 158-162.
11. Moreno, S.; Galván, E. M.; Vázquez, N.; Fiorilli, G.; Guido, P. C. Antibacterial efficacy of *Rosmarinus officinalis* phytochemicals against nosocomial multidrug-resistant bacteria grown in planktonic culture and biofilm. In *The Battle Against Microbial Pathogens: Basic Science, Technological Advances and Educational Programs*, 1st ed.; Formatex: Badajoz, Spain, **2015**; pp. 3-8.
12. Blom, N.; Sicheritz-Ponten, T.; Gupta, R.; Gammeltoft, S.; Brunak, S. Prediction of post-translational glycosylation and phosphorylation of proteins from the amino acid sequence. *Proteomics* **2004**, 4, 1633-49.
13. Gupta, R.; S. Brunak. Prediction of glycosylation across the human proteome and the correlation to protein function. In *Pac Symp Biocomput*, **2002**, 7, 310-322.
14. Wilkins, M.R.; Gasteiger, E.; Bairoch, A.; Sanchez, J.C.; Williams, K.L.; Appel, R.D.; Hochstrasser, D.F. Protein identification and analysis tools in the ExPASy server. *Methods Mol Biol*, **1999**, 112, 531-52.
15. Sonnhammer, E.L.; von Heijne, G.; Krogh, A.A. hidden Markov model for predicting transmembrane helices in protein sequences. *Proc Int Conf Intell Syst Mol Biol*, 1998. 6, 175-182.
16. Zhang, Y. I-TASSER server for protein 3D structure prediction. *BMC Bioinformatics* **2008**, 9, 40.
17. Roy, A.; Kucukural, A.; Zhang, Y. I-TASSER: a unified platform for automated protein structure and function prediction. *Nat Protoc* **2010** 5, 725-738.
18. Basharat, Z.; Yasmin, A. Energy landscape of a GSTP1 polymorph linked with cytological function decay in response to chemical stressors. *Gene* **2017**, 609, 19-27.
19. Singh, S.; Bharti, N.; Mohapatra, P. P. Chemistry and biology of synthetic and naturally occurring antiamoebic agents. *Chem Rev* **2009** 109, 1900-1947.
20. Seidel, J. S.; Harmatz, P.; Visvesvara, G. S.; Cohen, A.; Edwards, J.; Turner, J. Successful treatment of primary amebic meningoencephalitis. *New England J Med* **1982**, 306, 346-348.
21. Schuster, F. L.; Guglielmo, B. J.; Visvesvara, G. S. *In-vitro* activity of miltefosine and voriconazole on clinical isolates of free-living amebas: *Balamuthia mandrillaris*, *Acanthamoeba* spp., and *Naegleria fowleri*. *J Eukaryotic Microbiol* **2006**, 53, 121-126.

22. Goswick, S. M.; Brenner, G. M. Activities of azithromycin and amphotericin B against *Naegleria fowleri* *in vitro* and in a mouse model of primary amebic meningoencephalitis. *Antimicrob Agents Chemother* **2003** 47, 524-528.
23. Soltow, S. M.; Brenner, G. M. Synergistic activities of azithromycin and amphotericin B against *Naegleria fowleri* *in vitro* and in a mouse model of primary amebic meningoencephalitis. *Antimicrob Agents Chemother* **2007**, 51, 23-27.
24. Cope, J. R.; Conrad, D. A.; Cohen, N.; Cotilla, M.; DaSilva, A.; Jackson, J.; Visvesvara, G. S. Use of the novel therapeutic agent miltefosine for the treatment of primary amebic meningoencephalitis: report of 1 fatal and 1 surviving case. *Clin Infect Dis* **2016** 62, 774-776.
25. Heggie, T. W.; Küpper, T. Surviving *Naegleria fowleri* infections: A successful case report and novel therapeutic approach. *Travel Med Infect Dis* **2016** (In press) DOI: 10.1016/j.tmaid.2016.12.005.
26. Baig, A. M.; Khan, N. A. Novel chemotherapeutic strategies in the management of primary amoebic meningoencephalitis due to *Naegleria fowleri*. *CNS Neurosci Therap*, **2004**, 20, 289-290.
27. Baig, A. M.; Kulsoom, H.; Khan, N. A. Primary amoebic meningoencephalitis: amoebicidal effects of clinically approved drugs against *Naegleria fowleri*. *J Med Microbiol* **2014**, 63, 760-762.
28. Capewell, L.G.; Harris, A.M.; Yoder, J.S.; Cope, J.R.; Eddy, B.A.; Roy, S.L.; Visvesvara, G.S.; Fox, L.M.; Beach, M.J. Diagnosis, clinical course, and treatment of primary amoebic meningoencephalitis in the United States, 1937–2013. *J Pediatric Infect Dis Soc* **2014**, p.piu103.
29. Linam, W.M.; Ahmed, M.; Cope, J.R.; Chu, C.; Visvesvara, G.S.; da Silva, A.J.; Qvarnstrom, Y.; Green, J. Successful treatment of an adolescent with *Naegleria fowleri* primary amebic meningoencephalitis. *Pediatrics* **2015**, 135, e744-e748.
30. Rice, C. A.; Colon, B. L.; Alp, M.; Göker, H.; Boykin, D. W.; Kyle, D. E. Bis-benzimidazole hits against *Naegleria fowleri* discovered with new high-throughput screens. *Antimicrob Agents Chemother* **2015** 59, 2037-2044.
31. Win, N.N.; Ito, T.; Win, Y.Y.; Ngwe, H.; Kodama, T.; Abe, I.; Morita, H. Quassinoids: Viral protein R inhibitors from *Picrasma javanica* bark collected in Myanmar for HIV infection. *Bioorganic Med Chem Lett* **2016**, 26, 4620-4624.
32. Ryu, S.M.; Kwon, J.; Seo, Y.H.; Song, E.G.; Hong, S.S.; Kim, B.S.; Hong, J.S.; Ryu, K.H.; Lee, D. Quassinoids isolated from *Brucea javanica* inhibit pepper mottle virus in pepper. *Virus Res* **2017**, 227, 49-56.
33. Jiwajinda, S.; Santisopasri, V.; Murakami, A.; Kawanaka, M.; Kawanaka, H.; Gasquet, M.; Eilas, R.; Balansard, G.; Ohigashi, H. *In vitro* anti-tumor promoting and anti-parasitic activities of the quassinoids from *Eurycoma longifolia*, a medicinal plant in Southeast Asia. *J Ethnopharmacol* **2002** 82, 55-58.
34. Tong, K.L.; Chan, K.L.; AbuBakar, S.; Low, B.S.; Ma, H.Q.; Wong, P. F. The *in vitro* and *in vivo* anti-cancer activities of a standardized quassinoids composition from *eurycoma longifolia* on Incap human prostate cancer cells. *PloS one* **2015**, 10, e0121752.